Dominari Holdings Inc
NASDAQ:DOMH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (3.8), the stock would be worth $20.49 (637% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.5 | $2.78 |
0%
|
| 3-Year Average | 3.8 | $20.49 |
+637%
|
| 5-Year Average | 3.8 | $20.49 |
+637%
|
| Industry Average | 6.7 | $36.66 |
+1 219%
|
| Country Average | 2.4 | $13.26 |
+377%
|
Forward P/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Dominari Holdings Inc
NASDAQ:DOMH
|
62.9m USD | 0.5 | -2.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | 5.9 | 86.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 5 | 23.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 5.4 | 18.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 9 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 5.1 | 16.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.6B EUR | 11.5 | 36.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.6B AUD | 2.7 | 29.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Dominari Holdings Inc
Glance View
Dominari Holdings Inc., formerly AIkido Pharma Inc., is a biotechnology company. The Company has a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The Company’s pipeline consists of patented technology from universities and researchers. The Company advances its therapeutic drug pipeline through a collaboration with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. Its pancreatic drug candidate, DHA-dFdC, is a chemotherapy treatment for advanced pancreatic cancer.
